Cisplatin binding protein

Author: drtm

August undefined, 2024

WebCisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus by Umma Habiba 1,2,*, Elora Hossain 3, Aya Yanagawa-Matsuda 4, Abu Faem Mohammad Almas Chowdhury 5, Masumi Tsuda 1,6,7, Asad-uz- Zaman 2, Shinya Tanaka 1,6,7 and Fumihiro Higashino 3,4,* 1 WebMar 25, 2024 · Given that apoptosis resistance is one of the causes of the cisplatin resistance of tumor cells, our aim was to determine the relationship between RRS1 and cisplatin resistance in breast cancer cells. Here, we report that RRS1 is associated with cisplatin resistance in breast cancer cells.

Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma …

WebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). ... belonging to the USP protein family, reacts with the 26S proteasome complex and … WebTherefore, the study is designed to investigate the regulatory function and mechanism of Taurine up-regulated gene 1 (TUG1) in the cisplatin resistance of CRC. qRT-PCR checked the expressions of TUG1, Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), and miR-195-5p in CRC tissues and cells. bison best rotomolded cooler

Ribosome Biogenesis Regulator 1 Homolog (RRS1) Promotes Cisplatin …

WebApr 13, 2024 · HIGHLIGHTS. who: Florentine S. B. Subtil et al. from the Department of Radiotherapy and Radiooncology, Philipps-University, Marburg, Germany have published the research: Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines, in the … WebCisplatin is a chemotherapy drug which is used to treat cancers including: sarcoma, small cell lung cancer, germ cell tumors, lymphoma, and ovarian cancer. While it is often … WebAug 19, 2005 · Cisplatin is a widely used anti-tumor agent for the treatment of testicular and ovarian cancers. Carboplatin is used extensively for small cell, non small cell lung cancer … darpa one shot

Targeted therapy for cisplatin‐resistant lung cancer via …

Cellular responses to cisplatin. The roles of DNA-binding proteins …

WebTherapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and to develop new approaches for overcoming resistance, we generated long-term cisplatin treated (LTT) UC cell lines, characterised their cisplatin response, and determined the expression of … WebFull article: Insulin-like growth factor 2 mRNA-binding protein 2-stabilized long non-coding RNA Taurine up-regulated gene 1 (TUG1) promotes cisplatin-resistance of colorectal cancer via modulating autophagy Home All Journals Bioengineered List of Issues Volume 13, Issue 2 Insulin-like growth factor 2 mRNA-bindin .... Bioengineered darpa oversightWebMar 27, 2024 · Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus Cancers (Basel). 2024 Mar 27;12 (4):809. doi: 10.3390/cancers12040809. Authors darpa i2o open office baa

"WebCisplatin, cis - [PtCl 2 (NH 3) 2 ], is extensively used for the treatment of testicular and ovarian cancers and increasingly against other types of solid tumors (head/neck, lung, cervical, and bladder) ( 1 , 2 , 3 , 4 ). The cytotoxic effect of cisplatin is thought to be due to attack on DNA bases and induction of apoptosis in cancer cells ( 5 , 6 " - Cisplatin binding protein

Cisplatin binding protein

Cisplatin Binding Sites on Human Albumin* - Journal of Biological Chemistry

WebJun 20, 2024 · Cisplatin [ cis- diamminedichloroplatinum (II) ( cis -DDP)] is one of the most successful anticancer agents effective against a wide range of solid tumors. However, its … WebThe combination of adenoviruses and chemotherapy agents is a novel approach for human cancer therapeutics. A meticulous analysis between adenovirus and chemotherapeutic …

Did you know?

WebMay 26, 2024 · Using the fluorescent cisplatin analog BODIPY-cisplatin, two-dimensional gel electrophoresis, and mass spectrometry, we identified the protein binding partners in A2780 and cisplatin-resistant A2780cis ovarian carcinoma, as well as in HCT-8 and oxaliplatin-resistant HCT-8ox colorectal cell lines. WebJun 13, 2005 · Protein binding Cisplatin does not undergo instantaneous and reversible binding to plasma protein that is characteristic of normal drug-protein binding. However, the platinum itself is capable of binding to plasma proteins, including albumin, transferrin, and gamma globulin.

WebMay 15, 2016 · We summarize the structural features of known cisplatin-protein adducts. • Key characteristics of the cisplatin modes of binding to proteins are described. • …

WebSep 1, 2024 · Cisplatin for injection, USP, a platinum-based drug for intravenous use, is a white to light yellow lyophilized powder. Each vial of Cisplatin for injection, USP contains … WebJun 15, 2024 · Wang et al. indicated that miR-17 targets c-Jun activation domain binding protein 1 (JAB1) to promote tumor growth and cisplatin (DDP) resistance of TNBC . As far as we know, chemotherapy is the standard therapeutic strategy for TNBC, and DDP is the most widely used chemotherapeutic drug for solid tumors.

WebDec 22, 2007 · D and E carboxylate oxygen atoms and M thioether sulfur atoms are kinetically preferred binding sites for cisplatin in competition with DNA nucleobase nitrogens, and it has been postulated that initial κ S coordination by methionine-containing proteins may play a role in the mechanism of the anticancer drug [ 14, 15 ].

WebMay 26, 2024 · Using the fluorescent cisplatin analog BODIPY-cisplatin, two-dimensional gel electrophoresis, and mass spectrometry, we identified the protein binding partners in … darpa other transactionWebJun 3, 2013 · To identify proteins that bind to cisplatin, we synthesized two different platinum-agarose conjugates, one with two amino groups and another with two chlorides attached to platinum that are available for … darpa office locationsWebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying novel biomarkers to improve the diagnosis and treatment of NSCLC is important. darpa office of general counselWebCisplatin is a platinum-based drug which acts by binding to DNA by forming intrastrand cross-link conjugate which eventually leads to apoptosis due to the activation of p53, … bison billiards tournaments resultsWebJun 3, 2013 · To identify proteins that bind to cisplatin, we synthesized two different platinum-agarose conjugates, one with two amino groups and another with two chlorides attached to platinum that are available for protein binding, and conducted pull-down assays using cochlear and kidney cells. darpa office arlingtonWebThe protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively. To investigate the protein-binding properties of albumin with cisplatin, carboplatin and oxaliplatin, inductively coupl … bison beverage cheyenne wyWebThese results indicated that SSDBP1 may induce cell chemoresistance of cisplatin through promoting DNA repair, resistance-related gene expression, cell proliferation, and inhibiting apoptosis. ... Data show that single-stranded DNA binding protein 1 (hSSB1/NABP2/OBFC2B) forms a tetramer and is stabilized by two cysteines (C81 and … bison bifold wallet